title: HDFx: a novel biologic immunomodulator is therapeutically -effective in hemorrhagic and intestinal-ischemic shock: importance of microcirculatory-immunological interactions and their potential implications for the warfighter and disaster victims.
abstract: Recently, we have reported on the discovery of a new, conserved protein (35-40 kD), termed HDFx, that protects rats, guinea-pigs, mice and rabbits against lethal hemorrhage, endotoxins, and traumatic injury when given, systemically, as a pretreatment. HDFx was also found to stimulate several arms of the immune system. The present report demonstrates, for the first time, that HDFx ,when administered post-hemorrhage and post-intestinal ischemia shock -trauma, yields increased survival rates, elevates falling arterial blood pressures, possesses unique actions in the microvasculature, stimulates depressed RES phagocytosis (normally observed in animals and humans during blood loss, sepsis and trauma), and preserves cytokine levels in lymphocytes obtained from animals subjected to hemorrhage and traumatic shock. We believe that HDFx presents a potential brand new therapeutic approach:1)for the injured warfighter on the battlefield, 2)for victims of major disasters, 3)as an adjunct for patients undergoing high -risk surgical procedures commonly found in open-heart surgery, cancers, and in neurosurgeries. Use of HDFx could potentially allow oncologists to decrease chemotherapy dosing, while increasing patient survival chances.
authors.affiliation: Department of Physiology and Pharmacology, State University of New York, Downstate Medical Center, Brooklyn, New York 11203, USA. baltura@downstate.edu
authors.forename: Burton M
authors.initials: BM
authors.lastname: Altura
authors.forename: Anthony
authors.initials: A
authors.lastname: Carella
authors.forename: Asefa
authors.initials: A
authors.lastname: Gebrewold